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The latency-associated transcript (LAT) is essential for the wild-type herpes simplex virus type 1 (HSV-1)
high-reactivation phenotype since LAT mutants have a low-reactivation phenotype. We previously reported
that LAT can decrease apoptosis and proposed that this activity is involved in LAT’s ability to enhance the
HSV-1 reactivation phenotype. The first 20% of the primary 8.3-kb LAT transcript is sufficient for enhancing
the reactivation phenotype and for decreasing apoptosis, supporting this proposal. For this study, we con-
structed an HSV-1 LAT mutant that expresses the baculovirus antiapoptosis gene product cpIAP under
control of the LAT promoter and in place of the LAT region mentioned above. Mice were ocularly infected with
this mutant, designated dLAT-cpIAP, and the reactivation phenotype was determined using the trigeminal
ganglion explant model. dLAT-cpIAP had a reactivation phenotype similar to that of wild-type virus and
significantly higher than that of (i) the LAT mutant dLAT2903; (ii) dLAT1.5, a control virus containing the
same LAT deletion as dLAT-cpIAP, but with no insertion of foreign DNA, thereby controlling for potential
readthrough transcription past the cpIAP insert; and (iii) dLAT-EGFP, a control virus identical to dLAT-
cpIAP except that it contained the enhanced green fluorescent protein open reading frame (ORF) in place of
the cpIAP ORF, thereby controlling for expression of a random foreign gene instead of the cpIAP gene. These
results show that an antiapoptosis gene with no sequence similarity to LAT can efficiently substitute for the
LAT function involved in enhancing the in vitro-induced HSV-1 reactivation phenotype in the mouse.
Herpes simplex virus type 1 (HSV-1) establishes lifelong
latent infections in host sensory neurons. This virus is wide-
spread in the general population. When the eye is infected, the
virus spreads from epithelial cells to the peripheral nerve end-
ings and then travels to the trigeminal ganglia (TG) via retro-
grade axonal transport and establishes latent infection in sen-
sory neurons of the TG. During neuronal latency, HSV-1 has
no apparent impact on the infected individual. However, the
latent virus can reactivate sporadically throughout the life of
the individual. This occurs through a mechanism or mecha-
nisms that are currently not fully understood. HSV-1 reactiva-
tion in the TG results in the virus returning to the eye via
anterograde axonal transport. At the eye, reactivated HSV-1
can replicate, and infectious virus is shed in tears. Recurrent
ocular HSV-1 infection may cause corneal disease leading to
corneal scarring and loss of vision. Consequently, HSV-1 is one
of the most common infectious causes of corneal blindness in
the developed world.
During HSV-1 neuronal latency, the latency-associated tran-
script (LAT) is the only abundantly transcribed viral gene (39,
45). The primary LAT transcript is approximately 8.3 kb long
(11, 53) and partially or completely overlaps three viral genes,
those encoding AL, ICP0, and ICP34.5, in an antisense direc-
tion (33, 39, 45). A very stable intron, the 2-kb LAT, is spliced
from the primary transcript (12) and is the major LAT RNA
detected during latency (11, 42, 44, 50–52). LAT mutants
have impaired reactivation phenotypes in small-animal models
(3, 9, 17, 23, 29, 36, 40, 43), indicating that a LAT function
enhances the HSV-1 reactivation phenotype. However, the
nature of this LAT function remains unresolved.
It has been proposed that LAT may affect the latency reac-
tivation cycle by (i) antisense regulation of the important im-
mediate-early genes for ICP0 and/or ICP4 (via an extended
LAT transcript of approximately 15 kb) (6, 13, 39, 45), (ii)
association of the stable 2-kb LAT with ribosomes (26), and/or
(iii) expression of a LAT protein that can substitute for an
ICP0 function (46). However, a LAT function capable of fully
supporting the wild-type reactivation phenotype maps to
within the first 1.5 kb of the primary LAT transcript (i.e., LAT
nucleotides [nt] 1 to 1,499) (4, 32), which contains only LAT
exon 1 and the first 42% (837 nucleotides) of the stable 2-kb
LAT intron. This region of LAT does not overlap with the
ICP0 or ICP4 gene, does not contain the open reading frame
(ORF) encoding the putative LAT protein, and does not retain
the stability of the 2-kb LAT (32). Thus, LAT can support the
wild-type reactivation phenotype in rabbits (32) and mice (30)
by a mechanism that does not involve antisense regulation of
ICP0 or ICP4, does not require expression of the entire 2-kb
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LAT intron, does not require the presence of a stable LAT
RNA, and does not require expression of the putative LAT
protein with ICP0-like functions.
Although there has been some controversy regarding LAT’s
antiapoptosis activity (47), it has been reported that (i) plas-
mids expressing LAT have antiapoptosis activity in the absence
of other viral genes (1, 19, 20, 28), (ii) LAT has antiapoptosis
activity in the context of the virus in infected tissue culture cells
(16, 21), and (iii) LAT mutants appear to have increased
apoptosis in rabbit and mouse TG in vivo compared to LAT
viruses (1, 4a, 28). We have mapped LAT’s antiapoptosis ac-
tivity to the first 1.5 kb of the primary LAT transcript (19, 20),
the same region to which we previously mapped LAT’s ability
to enhance the HSV-1 reactivation phenotype (32). Collec-
tively, these observations support our hypothesis that LAT’s
antiapoptosis activity is crucial for the latency reactivation cy-
cle.
Recently, we showed that the bovine herpesvirus 1 (BHV-1)
LAT homologue, the LR gene, can efficiently substitute for the
LAT function involved in supporting the wild-type HSV-1 re-
activation phenotype (34). This ability was abrogated by inhib-
iting expression of the LR protein encoded by ORF-2 (25).
Although this LR protein has antiapoptosis activity (25), it also
has additional activities that have not been ruled out for LAT.
For example, the LR gene can inhibit cell growth, interact with
cyclin-dependent kinase 2/cyclin complexes, inhibit transcrip-
tion of the BHV-1 immediate-early 1 promoter, and inhibit
bICP0 RNA expression (5, 10, 14, 41). Since LAT and LR are
functional homologues that could share a non-antiapoptosis-
related function involved in the wild-type reactivation pheno-
type, these studies supported, but did not prove, the hypothesis
that LAT enhances the reactivation phenotype via its anti-
apoptosis activity. Therefore, we constructed and analyzed
dLAT-cpIAP. In this HSV-1 mutant, both copies of the region
of LAT that supports the reactivation phenotype (LAT nt 76 to
1667) were removed and replaced by the baculovirus inhibitor
of apoptosis gene cpIAP (from Cydia pomonella granulosis
virus) (2, 7, 8, 18, 48). cpIAP functions as an inhibitor of the
caspase family of apoptotic proteases. Since LAT and the
cpIAP gene are unrelated, it is extremely unlikely that they
share an undetermined non-antiapoptosis-related function.
We report here that dLAT-cpIAP had a wild-type reactivation
phenotype in the TG explant reactivation mouse model. This
strongly suggests that LAT’s antiapoptosis activity is sufficient
to account for LAT’s ability to support the wild-type HSV-1
reactivation phenotype.
MATERIALS AND METHODS
Cell lines. Rabbit skin (RS) cells, CV-1 cells, and Neuro2A cells (CCL 131;
American Type Culture Collection) were maintained in Eagle minimal essential
medium (MEM) with 2 mM L-glutamine, 0.1 mM nonessential amino acids, 1
mM sodium pyruvate, 10% fetal bovine serum (Promega Scientific), penicillin
(100 U/ml), and streptomycin (100 g/ml) (Sigma, St. Louis, MO).
Viruses. All parental and mutant viruses were triply plaque purified and
passaged only one or two times in rabbit skin (RS) cells prior to use. The
wild-type McKrae (wt), dLAT2903, dLAT1.5, and dLAT-EGFP viruses have
been previously described (29, 30, 37).
Apoptosis in tissue culture cells. As previously described (21), Neuro2A cells
(1 106 to 2 106) were seeded into six-well plates 2 days prior to infection and
maintained throughout in medium with 0.5% fetal bovine serum. Cells were
infected with 5 PFU/cell. Apoptosis was examined at 24 h postinfection using a
modified DNA laddering assay as previously described (21).
Construction of dLAT-cpIAP. Plasmid pLAT5.6 was constructed by cloning
the SwaI-to-MluI LAT locus (corresponding to 800 bp of the LAT promoter and
the first 2,850 bp of the primary 8.3-kb LAT) into the BamHI site of pNEB193.
The plasmid was digested with StyI and HpaI to remove a StyI-HpaI region
corresponding to LAT nt 76 to 1667. BamHI linkers were added, followed by
ligation. The resulting plasmid, pNEBLAT, thus contains HSV-1 DNA corre-
sponding to LAT nt 800 to 76, followed by a BamHI site, followed by LAT
nt 1667 to 2850. A plasmid containing the cpIAP gene (IAP-3 gene from
Cydia pomonella granulosis virus) was a gift from L. K. Miller (Department of
Genetics, University of Georgia, Athens). The complete cpIAP ORF, including
36 bp upstream of the ATG initiation codon and 104 bp downstream of the TAA
stop codon, was PCR amplified, cloned into pCRII-TOPO (Invitrogen, Inc.), and
subsequently cloned into the EcoRI site of plasmid pTRE (Clontech, Inc.). BglII
linkers were added to the beginning of the cpIAP ORF and the end of the simian
virus 40 (SV40) poly(A) signal (nt 488 to 1087 of pTRE) using the PCR-TOPO
cloning method. The entire cpIAP ORF sequence and SV40 poly(A) signal
sequence were isolated following BglII digestion and cloned into the BamHI
restriction site of pNEBLAT between LAT nt 76 and 1667. The resulting plas-
mid, pNEBLAT-IAP, was verified by DNA sequencing. It was then cotransfected
with infectious dLAT2903 genomic DNA into RS cells to generate the mutant
dLAT-cpIAP by homologous recombination, as previously described for the
construction of other HSV-1 mutants (29, 30, 35). Briefly, the cotransfection mix
was plated on RS cells, individual viral plaques were analyzed by restriction
digestion and Southern analysis, and plaques containing mixtures of wt and
mutant virus were repeatedly replated and analyzed until all of the plaques
appeared free of wt virus. Those plaques were then triply plaque purified, and the
structure of the virus was confirmed as described above. In the resulting chimeric
virus, dLAT-cpIAP, LAT nt 76 to 1667 are replaced by the complete cpIAP ORF
followed by the SV40 poly(A) signal sequence, thus placing cpIAP under control
of the intact LAT promoter.
Southern analyses. Briefly, viral DNA was digested with BamHI; the restric-
tion fragments were separated in a 1% agarose gel, transferred to Zeta paper,
rinsed in 2 SSC (1 SSC is 0.15 M NaCl plus 0.015 M sodium citrate) for 5 min,
and cross-linked to the membrane by UV light; and DNA-DNA hybridization
was performed with 32P-labeled probes as previously described (29, 30, 35).
Mice. Eight- to 10-week-old Swiss-Webster female mice (Jackson Labs) were
used for all experiments. Viral infections were done without corneal scarification
as we previously described (29, 30, 35).
RNA isolation. Total RNA was isolated from individual cell monolayers, each
from one well of a six-well plate. Isolations were performed using Trizol followed
by a treatment with 0.1 U of DNase I (Roche) in Tris-EDTA (pH 8.0) containing
100 mM MgCl2, 10 mM dithiothreitol, and 0.01 U of RNase inhibitor at 37°C for
30 min. The total RNA was then isolated using a GenElute Mammalian Total
RNA isolation kit (Sigma, St. Louis, MO).
Probes and primers. The LAT primers were OPUSQ (LAT nt 470 to 500;
CCACAACGGCCCGGCGCATGCGCTGTGGTT) for the LAT coding strand
and OPURS (LAT nt 646 to 615; TCTTTGTTGAACGACACCGGGCGCCC
TCGA) for the LAT anticoding strand. The cpIAP primers were cpIAPF2
(cpIAP ORF nt 141 to 161; AGTGGAGATAATGCGTTGGA) for the cpIAP
coding strand and cpIAPR2 (cpIAP ORF nt 517 to 497; GCAACGGTCGAAC
CATCTTA) for the cpIAP anticoding strand. The DNA IAP probe used for
Southern analysis of dLAT-cpIAP corresponds to a StyI-to-StyI restriction frag-
ment within the cpIAP ORF (IAP nt 77 to 481). The LAT DNA probe corre-
sponds to a NotI-to-AlwNI LAT restriction fragment (LAT nt 363 to 1677).
RT-PCR. First-strand cDNAs were synthesized from 0.5 g of total RNA using
the ThermoScript reverse transcription-PCR (RT-PCR) system (GIBCO) ac-
cording to the manufacturer’s recommendations. PCRs were performed in a
volume of 50 l consisting of 1 PCR buffer containing DNA polymerase, a 200
M concentration of each deoxynucleoside triphosphate, a 0.4 M concentration
of each primer, 1 mM MgSO4, 0.5 U of Platinum Pfx DNA polymerase
(GIBCO), and 2.5 l of completed RT reaction product. The reactions were
cycled 30 times at 94°C for 30 s, 60°C for 30 s, and 68°C for 30 s and then
extended once at 68°C for 7 min in a DNA thermal cycler (GeneAmp PCR
system 2700; PE Applied Biosystems). Ten microliters of each of the RT-PCR
products was separated in a 1.5% agarose gel in Tris-acetate-EDTA buffer and
then visualized by UV illumination after staining with 1 g/ml ethidium bromide.
Western blots. Total cell extracts were separated by 12% sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a
polyvinylidene difluoride membrane. The membrane was incubated with poly-
clonal rabbit anti-IAP antibody at a 1:200 dilution (Abcam Inc., Cambridge, MA)
and then washed, and the antibody bound to the blots was visualized by chemi-
luminescence with anti-rabbit immunoglobulin G (IgG) conjugated to horserad-
ish peroxidase (Chemicom, Inc.).
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Statistical analysis. Analyses were performed using the personal computer
program GraphPad Prism, version 4.00, for Windows (GraphPad Software, San
Diego, California).
RESULTS
Construction and genomic structure of dLAT-cpIAP. The
genomic structures of dLAT-cpIAP and the other viruses used
for this study are shown schematically in Fig. 1. All viruses
were derived from HSV-1 strain McKrae. Figure 1A shows the
prototypic structure of the wild-type HSV-1 McKrae genome.
The relative locations of the BamHI E (Bam E) and BamHI B
(Bam B) genomic restriction fragments are shown for refer-
ence. The viral long repeats (TRL and IRL) are expanded
(dashed lines) to show the relative locations and statuses of the
LAT gene and LAT region in each of the panels below. The
dashed lines cross to indicate that the repeats are inverted (i.e.,
the DNA sequences are in opposite orientations). The wild-
type and dLAT2903R LAT region is shown in panel B.
(dLAT2903R is marker-rescued dLAT2903, which is shown in
panel C.) The locations of the ICP0 and ICP34.5 mRNAs are
shown for reference. The primary LAT transcript in wild-type
virus and marker-rescued dLAT2903R is approximately 8.3 kb
(49, 50) (large arrow). A very stable and easily detected 2-kb
LAT (black rectangle) is an intron derived by splicing of the
primary LAT (12). The LAT region of dLAT2903 (panel C)
contains a deletion in both copies of LAT from 161 to
1,667 relative to the start of the primary LAT transcript
(indicated by “XXXXX”). This virus is missing key promoter
elements, makes no LAT RNA (indicated by a dashed line), is
a true LAT null mutant, and has a low reactivation phenotype
compared to wt HSV-1 (29). The construction of dLAT2903
and dLAT2903R has been previously described (29). The LAT
region of dLAT-cpIAP (panel D) contains the complete ORF
of the baculovirus cpIAP gene preceded by the entire LAT
promoter, including the portion missing in dLAT2903 (i.e.,
LAT nt 161 to 76). The cpIAP ORF is followed by the
SV40 polyadenylation signal sequence. This poly(A) signal se-
quence was cloned from and corresponds to nt 1066 to 1266 of
a BD Biosciences Clontech plasmid. dLAT-cpIAP thus con-
tains two complete copies of the cpIAP ORF (one in each viral
long repeat), each in place of LAT nt 76 to 1667 and driven by
the LAT promoter. The poly(A) site decreases the transcrip-
tion of LAT downstream of the cpIAP insertion to undetect-
able levels (represented by a dashed arrow; data not shown).
The structures of dLAT1.5 and dLAT-EGFP (panels E and F)
have been previously published (30, 37) and are discussed
below.
Because the cpIAP gene has no sequence homology to the
HSV-1 LAT gene, the construction of dLAT-cpIAP by homol-
ogous recombination required that the cpIAP gene was first
cloned into a plasmid containing appropriate HSV-1 flanking
sequences. This and additional details of the construction of
dLAT-cpIAP are given in Materials and Methods.
Confirmation of the dLAT-cpIAP genomic structure by
Southern blot analysis. dLAT-cpIAP viral DNA was purified
and digested with BamHI. Restriction digestion fragments
FIG. 1. Structure of the LAT region of dLAT-cpIAP and other viral mutants. (A) HSV-1 genomic structure. TRL and IRL indicate the viral
long repeats (terminal and internal, respectively). IRS and TRS indicate the viral short repeats. UL and US indicate the long and short unique
regions, respectively. The dashed lines indicate that the regions of the TRL and IRL are expanded below, with the TRL inverted relative to the
IRL so that both identical regions can be represented by a single image. (B) Wild-type (wt) and dLAT2903R (marker-rescued dLAT2903; see panel
C) LAT region. The intact LAT promoter is indicated by the shaded rectangle. The solid black rectangle indicates the stable 2-kb LAT. The relative
locations of ICP0 and ICP34.5 are shown for reference. (C) LAT dLAT2903 has a deletion of LAT nt 161 to 1667 (XXXXXX). dLAT2903
is a true LAT null mutant that is missing the primary LAT promoter elements between 161 and 1. dLAT2903 is also deleted for a putative
secondary LAT promoter, LAP2, located within the 5 end of the primary LAT transcript prior to the start of the 2-kb LAT (15). This mutant is
therefore not capable of expressing any LAT RNA (dashed lines) (29). (D) dLAT-cpIAP contains the antiapoptosis gene cpIAP followed by a
poly(A) signal inserted in place of LAT nt 76 to 1667. The entire LAT promoter is present. No LAT RNA is transcribed past the poly(A) site.
(E) dLAT1.5 is identical to dLAT-cpIAP, but with no inserted ORF or polyadenylation signal. The region of LAT past the deletion is transcribed
normally. (F) dLAT-EGFP is identical to dLAT-cpIAP, except that the irrelevant gene EGFP is inserted instead of cpIAP.
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were separated by agarose gel electrophoresis, transferred to a
Zeta membrane, and hybridized to a 32P-labeled NotI-AlwNI
(LAT nt 363 to 1677) restriction fragment (Fig. 2A). As
expected, only two BamHI restriction fragments are seen in
the McKrae (McK) and dLAT2903R (dLATR) lanes. The
larger band is BamHI B (10,139 bp; genomic nt 113,322 to
123,461, corresponding to LAT nt 5479 to 4660) (also see
Fig. 1A). This restriction fragment spans the junction between
the internal long repeat and the long unique region. The
smaller band is BamHI E (8,913 bp; genomic nt 2,905 to
11,818, corresponding to LAT nt 4253 to 4660), which
spans the junction between the terminal long repeat and the
long unique region (Fig. 1A). Thus, although the BamHI B and
E restriction fragments have one common restriction site at
LAT nt 4660 within the long repeats, they are different sizes
because the other restriction site of each fragment is in a
different location in the unique long region of the virus ge-
nome. The same two bands are seen with dLAT2903 (dLAT),
except that each is 1,828 bp shorter due to the deletion of LAT
nt 161 to 1667 (BamHI B, 8,311 bp; BamHI E, 7,085 bp).
dLAT-cpIAP has an additional BamHI site between the end of
the cpIAP ORF and the beginning of the poly(A) insertion
signal. Therefore, four BamHI restriction fragments are pre-
dicted, two from each of the modified BamHI B and E frag-
ments (5,200 bp and 3,595 bp from BamHI E and 6,690 bp and
3,591 bp from BamHI B). However, the predicted sizes of two
of these bands are very similar (3,595 and 3,591 bp) and appear
as one band. Thus, only three bands are seen in the dLAT-
cpIAP (IAP) lane. To further confirm the genomic structure of
dLAT-cpIAP in the LAT region, the probe was stripped from
the membrane shown in Fig. 2A, and the membrane was re-
probed with a cpIAP-specific probe. This probe corresponds to
a region within the cpIAP ORF (nt 77 to 481) and therefore
should hybridize only to the 5,200-bp and 6,686-bp IAP-con-
taining fragments. As seen in Fig. 2B, the cpIAP probe hybrid-
ized only to the expected bands (lane IAP) and did not hybrid-
ize to any bands in the McKrae (McK), dLAT2903 (dLAT),
and dLAT2903R (dLATR) lanes. These analyses confirmed
the correct genomic structure of dLAT-cpIAP in the LAT
region. Panel C shows analyses of viruses that were reactivated
following mouse TG explantation and is discussed below.
Tissue culture characterization of dLAT-cpIAP replication,
cpIAP mRNA expression, and cpIAP protein expression. CV-1
cells were infected at a multiplicity of infection (MOI) of 0.01
with dLAT-cpIAP, dLAT2903 (the immediate parental virus),
or wild-type McKrae (the parental virus for dLAT2903). Rep-
lication appeared similar for all three viruses (Fig. 3A), indi-
cating that the insertion of the cpIAP gene followed by the
SV40 poly(A) signal sequence in place of LAT nt 76 to 1667
did not significantly alter virus replication in tissue culture and
that the ICP0 gene was functioning correctly.
CV-1 cells were infected at an MOI of 5, and total RNA was
prepared at various times postinfection (p.i.). RT-PCR was
performed using cpIAP-specific primers corresponding to
cpIAP nt 141 to 160 and 517 to 497 or primers specific for LAT
exon 1 (the region prior to the stable 2-kb LAT intron) corre-
sponding to LAT nt 470 to 500 and 652 to 621. The RT-PCR
products were analyzed by agarose gel electrophoresis as de-
scribed in Materials and Methods (Fig. 3B and C). Lanes
labeled P are cpIAP products generated from cloned (plasmid)
DNA. A faint cpIAP RT-PCR product with the expected mo-
bility (376 bp) was detected at 4 h p.i. (Fig. 3B). The cpIAP
RT-PCR product was readily detectable at 6 h, and the inten-
sity of this band remained fairly constant until at least 28 h p.i.
A faint LAT RT-PCR product with the expected mobility (182
bp) was detected at 4 h p.i., while a more intense band was seen
from 6 to 28 h p.i. Thus, cpIAP RNA was expressed with
similar kinetics as LAT. As expected, no LAT or cpIAP RT-
PCR product was seen with RNAs from mock-infected cells or
when reverse transcriptase was left out of the reaction mix
(data not shown). Note that the LAT primers used generated
a LAT product from outside the stable 2-kb LAT. This was
done to eliminate any potential artifacts due to accumulation
of the stable 2-kb LAT.
RS cells were infected at an MOI of 5. Immediately after
infection (Fig. 3D; 0 h p.i.) or at 20 h p.i., total cell extracts
were subjected to SDS-PAGE, proteins were transferred to a
membrane, and Western analysis was performed using a
cpIAP-specific antibody. A band with the correct mobility for
cpIAP (33 kDa) was recognized by the cpIAP antibody in the
dLAT-cpIAP (lane cpIAP)-infected cells at 20 h p.i. (arrow),
but not in dLAT-cpIAP-infected cells immediately after infec-
tion or in dLAT2903 (dLAT)- or wt McKrae-infected cells at
either time p.i. The band migrating more slowly than the 62-
kDa molecular size marker is an unidentified cellular band that
also cross-reacts with the polyclonal rabbit serum in uninfected
RS cells (not shown). In summary, cpIAP was expressed during
productive infection and did not impair viral replication in
tissue culture.
The cpIAP protein expressed by dLAT-cpIAP is functional.
We previously developed a modified DNA ladder assay that
allows us to examine the ability of LAT, in the context of the
virus, to block apoptosis in infected Neuro2A cells (21). We
used this approach to confirm that the cpIAP protein seen in
the above Western blot was functional. Neuro2A cells were
infected with 5 PFU/cell of dLAT-cpIAP, wt McKrae, or
FIG. 2. Southern hybridization analysis of dLAT-cpIAP’s genomic
structure. dLAT-cpIAP viral DNA was purified and digested with
BamHI. Restriction digestion fragments were separated by agarose gel
electrophoresis, transferred to a Zeta membrane, and hybridized to a
32P-labeled NotI-AlwNI (LAT nt 363 to 1667) restriction fragment
(A and C). The membrane from panel A was stripped and reprobed
using a 32P-labeled probe specific for nt 141 to 517 of the cpIAP ORF.
Panels A and B show DNAs prepared from the viral stocks used for
this report. Panel C shows DNAs from reactivated viruses recovered
from latently infected mouse TG following explantation.
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dLAT2903. Apoptosis was examined at 24 h postinfection as
we previously described (21). For this assay, the harvested cells
are incubated in hypotonic buffer for 2 h at 4°C. This lyses the
cells without disrupting the nuclei and allows fragmented DNA
to be eluted from the nuclei while leaving the large unfrag-
mented chromosomal DNA trapped inside the nucleus. The
nuclei (and unfragmented chromosomal DNA) are removed
by centrifugation, and equal aliquots are subjected to electro-
phoresis. This results in both more “laddering” and more total
(fragmented) DNA in samples from apoptotic cultures. Trip-
licate independent samples were used to confirm the assay’s
reproducibility. Neuro2A cells infected with dLAT-cpIAP
(Fig. 4, lanes 1, 2, and 3) or the wild type (lanes 4, 5, and 6) had
less fragmented DNA than Neuro2A cells infected with
dLAT2903 (lanes 7, 8, and 9) or than uninfected cells (lanes 10,
11, and 12). Both LAT in Neuro2A cells infected with wt virus
and cpIAP in Neuro2A cells infected with dLAT-cpIAP virus
therefore appeared to decrease both the background level of
apoptosis seen in uninfected Neuro2A cell cultures and the
additional apoptosis induced following infection of Neuro2A
cells with the LAT mutant dLAT2903. It is extremely unlikely
that LAT nt 161 to 76 (present in dLAT-cpIAP but not in
dLAT2903) somehow contributed to dLAT-cpIAP’s antiapo-
ptosis activity, since we previously showed that this LAT region
does not have any detectable antiapoptosis activity (19). In
addition, DNA fragmentation in dLAT1.5 (which contains
these LAT sequences; Fig. 1E)-infected cells was indistinguish-
able from that in dLAT2903-infected cells (not shown). Thus,
in dLAT-cpIAP, the cpIAP ORF followed by the SV40
poly(A) signal sequence and driven by the LAT promoter
appeared capable of substituting for the deleted LAT region in
terms of blocking apoptosis in the context of the virus. This
indicated that the cpIAP protein expressed by dLAT-cpIAP
was functional.
Replication of dLAT-cpIAP in mouse eyes. Eight-week-old
Swiss Webster mice were infected with 2  105 PFU of dLAT-
cpIAP, dLAT2903, wild-type McKrae, dLAT1.5, or dLAT-
EGFP/eye as described in Materials and Methods. Tear swabs
were collected from 10 eyes/group at various times, and the
amount of infectious virus in each swab was determined by a
standard plaque assay on RS cell monolayers (Fig. 5). All of
the viruses replicated to similar peak titers, suggesting that
dLAT-cpIAP replicated normally in mouse eyes.
cpIAP RNA is expressed in TG of mice latently infected with
dLAT-cpIAP. Mice were infected with 2  105 PFU of dLAT-
cpIAP/eye as described above. At 30 days p.i., the mice were
euthanized, TG were removed, and the total RNA from indi-
vidual TG was subjected to RT-PCR analysis using cpIAP-
specific primers as described above for cpIAP RNA in infected
tissue culture cells (Fig. 6). Lane M shows the PCR product
FIG. 3. Characterization of dLAT-cpIAP in tissue culture.
(A) Replication in CV-1 cells. Cell monolayers were infected with virus
at a low MOI of 0.01. At the indicated times, infected cell monolayers
with culture medium were harvested and freeze-thawed to release
virus, and the amount of total infectious virus was determined using
standard plaque assays. (B and C) cpIAP RNA expression in dLAT-
cpIAP-infected CV-1 cells. CV-1 cell monolayers were infected with
dLAT-cpIAP (B) or wild-type McKrae (C) at an MOI of 5. Total
RNAs were isolated at the indicated times p.i. (hours), and RT-PCRs
were performed using primers specific for cpIAP or LAT (see Mate-
rials and Methods and the text). Lanes: P, PCR of cloned DNA as
marker; M, DNA size markers (numbers represent base pairs).
(D) Western blot detection of cpIAP expressed by dLAT-cpIAP. RS
cells were infected at an MOI of 5, and cell extracts were prepared
immediately following infection (0 h p.i.) and at 20 h p.i. Extracts were
separated by SDS-PAGE, transferred to a polyvinylidene difluoride
membrane, and probed using a cpIAP-specific antibody (Abcam, Inc.).
Lanes: dLAT, dLAT2903-infected cells; wt, wild-type McKrae; cpIAP,
dLAT-cpIAP; M, molecular size marker; mock, mock-infected cells.
The lane between the mock lanes is empty. The arrow indicates the
location of the cpIAP band.
FIG. 4. Protection against DNA fragmentation by dLAT-cpIAP.
Neuro2A cells were infected with 5 PFU/cell of dLAT-cpIAP, wt
McKrae, or dLAT2903. At 24 h p.i., apoptotic DNA ladder assays were
performed in triplicate as previously described (21). All lanes are from
the same gel, but irrelevant lanes between lanes 9 and 10 were deleted
from the final image.
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obtained from a cpIAP-containing plasmid amplified using
identical primers to those used for RNAs isolated from TG
and acts as a positive control and a size marker. An RT-PCR
product corresponding in size to the marker in lane M was
detected using extracts from seven of the eight latently infected
TG (lanes 1 to 7). The variation in intensity of the cpIAP
RT-PCR products among lanes 1 to 7 is consistent with the
variation in HSV-1 genome copy numbers seen among indi-
vidual latently infected TG (40). Thus, as expected, the LAT
promoter in dLAT-cpIAP appeared to express cpIAP RNA
during latency.
Wild-type explant TG reactivation of dLAT-cpIAP. Mice
were infected with 2  105 PFU of dLAT-cpIAP, wt, or
dLAT2903/eye. On day 30 p.i., surviving mice were sacrificed,
and individual TG were cultured in tissue culture medium.
Aliquots of medium were removed from each culture daily for
up to 10 days and plated on indicator cells (RS cells) to look
for the presence of reactivated virus. The results are shown in
Fig. 7A. The decreased reactivation phenotype of LAT vi-
ruses compared to that of wt viruses in the mouse explant TG
model is often only apparent when the time to the reactivation
event is examined rather than just determining the percentage
of TG from which reactivated viruses are detected at some
arbitrary late time point after explantation (43). Since survival
analysis (Kaplan-Meier) is appropriate for any kind of exper-
iment where the result is expressed as the time to a well-
defined end point, we feel that this analysis is preferable to
chi-square (or Fisher’s exact) analysis. The reactivation phe-
notypes of dLAT-cpIAP and wt were similar (P  0.5), and
both were significantly higher than that of LAT dLAT2903
(P  0.003 for dLAT-cpIAP and 0.015 for wt). Thus, the
substitution of cpIAP for LAT nt 76 to 1667 appeared to have
“rescued” the LAT low-reactivation phenotype of dLAT2903
to the LAT-like high-reactivation phenotype in the mouse
model. This strongly suggests that the LAT function involved
in supporting the wt reactivation phenotype in mice can be
replaced by an alternative antiapoptosis gene. To confirm that
the virus recovered from the explanted TG was the correct
input virus, reactivated viruses from some of the cultures were
analyzed by Southern blotting (Fig. 2C). As expected, the re-
sults shown in the lanes labeled IAP confirmed that the virus
recovered from the explanted TG of latently dLAT-cpIAP-
infected mice was dLAT-cpIAP.
Low-reactivation phenotype of dLAT1.5 and dLAT-EGFP in
mice. A second, independent experiment was done in which
two additional mutants, dLAT1.5 and dLAT-EGFP, were in-
cluded as controls (Fig. 7B and C). dLAT1.5 contains the same
LAT deletion as dLAT-cpIAP (LAT nt 76 to 1667) but does
not contain any foreign DNA insert (30) (Fig. 1E). In addition,
dLAT1.5 transcribes all of LAT past nt 1667 (i.e., past the
location of the cpIAP insert in dLAT-cpIAP). dLAT-EGFP is
identical to dLAT-cpIAP, except that it contains the enhanced
green fluorescent protein (EGFP) gene in place of cpIAP (37)
(Fig. 1F). dLAT1.5 acts as a control for the unlikely possibility
that LAT nt 161 to 76 (present in dLAT-cpIAP and
dLAT1.5 but absent from dLAT2903) or a small amount of
LAT transcription past the cpIAP-SV40 poly(A) signal se-
quence inserted in dLAT-cpIAP might account for the LAT-
like wt reactivation phenotype of dLAT-cpIAP, while dLAT-
EGFP serves as a control for the insertion of an irrelevant gene
FIG. 5. Replication of dLAT-cpIAP in mouse eyes. Mice were ocu-
larly infected with 2 105 PFU/eye. Tear swabs were collected on days
3, 5, 7, and 10 p.i. Each symbol represents the average titer for each
group (n  10). Solid circles, wt McKrae; open circles, dLAT-cpIAP;
squares, dLAT2903; triangles, dLAT1.5; diamonds, dLAT-EGFP.
FIG. 6. Expression of cpIAP RNA in TG of mice latently infected
with dLAT-cpIAP. The total RNA was isolated from individual TG
(lanes 1 to 8) at 30 days p.i. with dLAT-cpIAP (initial infectious dose,
2  105 PFU/eye). RT-PCR was performed using the same cpIAP-
specific primers as those described for Fig. 3B, and the products were
run in a 2% agarose gel. Lane M, PCR of cloned cpIAP DNA, used as
a size marker. (A) Reverse transcriptase was included. (B) Reverse
transcriptase was not included.
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or DNA sequence into the LAT locus used for the insertion of
cpIAP into dLAT-cpIAP.
Mice were infected as described above, and on day 30 p.i.
TG explant reactivations were performed. As in the first mouse
experiment, dLAT-cpIAP had a reactivation phenotype signif-
icantly higher than that of dLAT2903 (Fig. 7B; P  0.003) and
similar to that of the wt (P 0.69). As expected, both dLAT1.5
and dLAT-EGPF had reactivation phenotypes significantly
lower than that of dLAT-cpIAP (Fig. 7C; P  0.01 and P 
0.02, respectively) and not significantly different from that of
dLAT2903 (P 0.63 and P 0.48, respectively). These results
are identical to those of studies with a rabbit ocular model in
which dLAT1.5 and dLAT-EGFP had reduced spontaneous
reactivation (compared to the wild type) that was indistinguish-
able from that of dLAT2903 (19, 37). As described above,
these statistical analyses are based on a Kaplan-Meier survival
curve analysis rather than just the final percentage of TG from
which virus was reactivated. Thus, neither readthrough LAT
transcription nor the insertion of irrelevant DNA can account
for the LAT-like reactivation phenotype of dLAT-cpIAP.
These findings therefore strongly support our hypothesis that
LAT’s antiapoptosis activity is sufficient for LAT’s ability to
support the wt reactivation phenotype.
DISCUSSION
We report here that replacing the HSV-1 LAT gene with the
inhibitor of apoptosis gene (cpIAP) resulted in a recombinant
virus with a reactivation phenotype similar to that of the wild-
type virus. This supports the hypothesis that LAT’s antiapo-
ptosis activity is a key LAT function involved in enhancing the
reactivation phenotype. cpIAP is a well-characterized inhibitor
of apoptosis from the baculovirus Cydia pomonella granulovi-
rus (2, 7, 8). It can block apoptosis by binding to caspase-9 (18,
48). The dLAT-cpIAP mutant inhibited apoptosis as efficiently
as the wild-type virus, as judged by DNA ladder assays of
extracts from acutely infected tissue culture cells, and fully
supported the wt TG-explant reactivation phenotype in the
mouse.
To eliminate both the influence of potential readthrough
transcription past the location of the inserted cpIAP gene
(LAT nt 1667) and the expression of a random foreign gene at
the location of the inserted cpIAP gene, in a second indepen-
dent experiment we compared dLAT-cpIAP to two additional
control viruses, namely, dLAT1.5, which contains the identical
LAT deletion with no foreign insertion and therefore controls
for potential readthrough transcription past LAT nt 1667, and
dLAT-EGFP, which is identical to dLAT-cpIAP except that it
contains the EGFP gene ORF in place of the cpIAP ORF and
therefore controls for expression of a random foreign gene at
the location of cpIAP. Again, dLAT-cpIAP had a significantly
higher reactivation phenotype than did dLAT2903 (P 0.003).
dLAT-cpIAP also had a significantly higher reactivation phe-
notype than those of both dLAT1.5 and dLAT-EGFP (P 
0.01 and P  0.02, respectively), which were similar to that of
dLAT2903 (P  0.4). The wild-type-like reactivation pheno-
type of dLAT-cpIAP was also not due to LAT nt161 to76,
which are present in dLAT-cpIAP but not in dLAT2903, be-
cause dLAT1.5, which had a reactivation phenotype similar to
that of dLAT2903, contains this region. In addition, we previ-
ously showed that LAT1.8A, a mutant expressing LAT nt 1 to
76 (and containing the entire LAT promoter and thus LAT nt
161 to 76), and LAT2.5A, a mutant expressing just LAT nt
1 to 661 (and also containing the LAT promoter), both have a
dLAT2903 (LAT null) reactivation phenotype in rabbits (19).
Thus, cpIAP efficiently substituted for LAT’s ability to enhance
the HSV-1 reactivation phenotype in the mouse model, sup-
porting our hypothesis that LAT’s antiapoptosis activity is crit-
ical for LAT’s ability to enhance the reactivation phenotype.
The LAT locus removed from dLAT2903 and replaced by
FIG. 7. Explant reactivation of dLAT-cpIAP from mouse TG.
(A) Experiment 1. Ten-week-old Swiss Webster mice were infected
with 2  105 PFU/eye. On day 30 p.i., individual TG (n  20/group)
were explanted into tissue culture medium. Aliquots were removed
daily and plated on indicator cells (RS cells) to look for the presence
and time of first appearance of reactivated virus. For dLAT-cpIAP
versus dLAT2903, P  0.003 by Kaplan-Meier survival analysis; for
dLAT-cpIAP versus wt, P  0.5. (B and C) Experiment 2. The exper-
iment was identical to experiment 1 except that mice were 8 weeks old
at the time of infection. For dLAT-cpIAP, n  24; for wt, n  16; for
dLAT2903, n 16; for dLAT1.5, n 12; for dLAT-EGFP, n 16. For
dLAT-cpIAP versus wt, P  0.7; for dLAT-cpIAP versus dLAT2903,
P  0.003; for dLAT-cpIAP versus dLAT1.5, P  0.01; for dLAT-
cpIAP versus dLAT-EGFP, P  0.02.
12292 JIN ET AL. J. VIROL.
 at UNIV O
F NEBRASKA-LINCO
LN on Septem






cpIAP in dLAT-cpIAP also contains AL, an HSV-1 gene an-
tisense to the 5 end of LAT that we recently discovered (33).
Thus, it is possible that cpIAP restored the wt reactivation
phenotype by substituting for an AL function rather than a
LAT function. However, our previous results obtained with the
mutant dLAT371 (30, 35) make this unlikely. dLAT371 is
deleted for LAT nt 76 to 447 (a StyI-StyI deletion). This de-
letion removes the 5 end of AL (the AL mRNA starts at LAT
nt 158, and the AL ORF starts at LAT nt 98), and no AL RNA
is expressed. However, all of LAT except for the deleted area
is expressed normally. dLAT371 has a wild-type reactivation
phenotype (35). Thus, dLAT371, a LAT AL mutant, and
dLAT-cpIAP, a LAT AL cpIAP mutant, both have wild-
type reactivation phenotypes. This strongly suggests that in the
absence of AL, cpIAP can substitute for LAT. Since the cpIAP
gene is a powerful antiapoptosis gene, these results strongly
argue that cpIAP can support the wt reactivation phenotype by
substituting for LAT’s antiapoptosis activity. This in turn
strongly supports the hypothesis that LAT’s antiapoptosis ac-
tivity is the key LAT function responsible for its ability to
support the wt reactivation phenotype.
LAT is the only HSV-1 gene abundantly transcribed during
neuronal latency. LAT mutants have a reduced or delayed
reactivation phenotype in mice and a reduced reactivation
phenotype in rabbits (3, 9, 17, 23, 29, 36, 40, 43). Thus, LAT
plays an important role in the HSV-1 latency-reactivation cy-
cle. However, the mechanism by which LAT enhances the
reactivation phenotype remains elusive, as does the determi-
nation of whether LAT’s effect on the reactivation phenotype
occurs during the establishment of latency, maintenance of
latency, reactivation from latency, or a combination of two or
more of these time periods. Although some reports, including
one from our lab, suggest that LAT mutants establish latency
less efficiently than LAT viruses, these findings do not dem-
onstrate that LAT’s effect on the establishment of latency is
key to, or in fact plays any significant role in, LAT’s ability to
enhance the reactivation phenotype. In fact, a mutant that
appears to establish latency significantly less well than LAT
viruses has a wild-type LAT-like reactivation phenotype in
rabbits (31). This argues that a decreased establishment of
latency by LAT mutants is unlikely to completely account for
the decreased reactivation phenotype of LAT viruses.
Although our initial report that LAT can block apoptosis
both in vitro and in vivo (28) became controversial because one
group suggested that our studies were flawed, LAT’s antiapo-
ptosis activity has since been confirmed by others (1). In addi-
tion, we have significantly extended our findings since our first
report of LAT’s antiapoptosis activity in 2000. We have shown
that (i) the region of LAT that decreases apoptosis comaps
with the region of LAT that supports the wild-type high-reac-
tivation phenotype (19, 20); (ii) LAT can block apoptosis in-
duced by the overexpression of either caspase-8 or caspase-9,
suggesting that LAT can block both major apoptosis pathways
(16, 20); (iii) LAT directly or indirectly affects the accumula-
tion of Bcl-xL and Bcl-xS transcripts that encode apoptotic
regulatory proteins (27); and (iv) the BHV gene LR, which has
antiapoptosis activity and is a functional homologue of the
HSV-1 LAT but has no sequence homology to LAT, can effi-
ciently substitute for the LAT function responsible for enhanc-
ing the reactivation phenotype (25, 34). Most importantly, we
showed here that the unrelated antiapoptosis gene cpIAP
could replace LAT and support the wt reactivation phenotype.
Thus, not only does LAT have antiapoptosis activity, but this
antiapoptosis activity appears to be responsible for the mech-
anism by which LAT enhances the reactivation phenotype.
Although HSV-1 has other antiapoptosis genes, LAT is the
only antiapoptosis gene that is expressed at the end of the
acute infection, a time when latency is likely being established
and at which it is crucial to enhance the survival of neurons
that suffered damage induced by virus infection. LAT is also
the only viral antiapoptosis gene expressed at high levels dur-
ing the maintenance of latency and when reactivation is trig-
gered. Thus, if preventing cell death by apoptosis is important
during the latency-reactivation cycle, then LAT is likely the
primary or only viral gene involved.
The mechanism by which LAT’s antiapoptosis activity en-
hances the reactivation phenotype is not yet known. In addi-
tion to LAT blocking virus-induced apoptosis in neurons, we
propose two additional potential mechanisms that we feel are
worthy of investigation. First, we hypothesize that the insults
that induce reactivation also lead to apoptosis. In fact, it is
possible that the initiation of apoptosis is what leads directly or
indirectly to HSV-1 reactivation. For instance, one or more
steps in the apoptosis pathways may trigger reactivation. LAT
would therefore be important in preventing an apoptosis-re-
lated reactivation trigger from killing the neuron prior to the
completion of reactivation. This differs from LAT protecting
the neuron from apoptosis induced by the virus, because in this
scenario LAT would play a critical role in the actual reactiva-
tion mechanism by preventing the reactivation trigger from
killing the neuron. In the same vein, it has previously been
shown that the induction of reactivation by dexamethasone in
rabbits latently infected with BHV results in significantly de-
creased levels of LR, the BHV functional homologue of LAT,
within 24 h. By 48 h, the LR levels return to normal (38). If
reactivation stimuli have a similar effect on LAT, it would
suggest that reducing LAT levels may lead to reactivation. We
propose that decreasing LAT levels allow apoptosis to begin,
thus triggering viral reactivation. The restoration of normal
LAT levels then attenuates apoptosis, allowing reactivation to
go to completion.
A second potential mechanism by which LAT’s antiapopto-
sis activity could lead to an enhanced reactivation phenotype
involves protection against T-cell-induced apoptosis. Recently,
it was shown that during latency some neurons are surrounded
by T cells, and it has been proposed that these T cells suppress
reactivation (22, 24). Cytotoxic T cells kill target cells, in part
by apoptosis. Thus, the high levels of LAT in some latently
infected neurons may act to prevent the elimination of these
neurons by T cells. This type of LAT-related immune evasion
could be important during the establishment of, maintenance
of, and/or reactivation from latency.
Whether LAT’s antiapoptosis activity functions to enhance
the reactivation phenotype by one or more of the above pro-
posed mechanisms or whether LAT’s antiapoptosis activity
functions via a different mechanism remains to be determined.
Regardless, the results presented here show that the replace-
ment of LAT by a well-known apoptosis inhibitor, cpIAP, is
sufficient to restore wt (LAT) reactivation to a LAT null
virus. This confirms that LAT’s antiapoptosis activity is directly
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or indirectly involved in the mechanism by which LAT en-
hances the reactivation phenotype.
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